RENATA Stock Overview
Renata Limited manufactures, markets, distributes, and exports human pharmaceuticals, animal health medicines, nutritionals, and vaccines in Bangladesh.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
Renata PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ৳786.90 |
| 52 Week High | ৳1,217.90 |
| 52 Week Low | ৳730.00 |
| Beta | 0.031 |
| 1 Month Change | -6.57% |
| 3 Month Change | -35.39% |
| 1 Year Change | -35.39% |
| 3 Year Change | -29.54% |
| 5 Year Change | -4.76% |
| Change since IPO | 26,901.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| RENATA | BD Pharmaceuticals | BD Market | |
|---|---|---|---|
| 7D | -2.6% | -2.0% | -2.3% |
| 1Y | -35.4% | -14.8% | -17.4% |
Return vs Industry: RENATA underperformed the BD Pharmaceuticals industry which returned -14.9% over the past year.
Return vs Market: RENATA underperformed the BD Market which returned -17% over the past year.
Price Volatility
| RENATA volatility | |
|---|---|
| RENATA Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in BD Market | 8.7% |
| 10% least volatile stocks in BD Market | 3.4% |
Stable Share Price: RENATA's share price has been volatile over the past 3 months.
Volatility Over Time: RENATA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1972 | 7,119 | Syed S. Kabir | www.renata-ltd.com |
Renata Limited manufactures, markets, distributes, and exports human pharmaceuticals, animal health medicines, nutritionals, and vaccines in Bangladesh. Its pharmaceutical products include antimicrobials, anti-hypertensive, anti-angina, anti-diabetic, eye-ear and topical preparation, antigout, NSAID, anti-spasmodic, steroid, anti-osteoporotic, anti-allergic, cardiovascular, CNS, hormone, anti-cancer, oxytocic, anti-fibrinolytic, anti-asthma, expectorant, oral rehydration saline, narcotic analgesic, antipyretic/analgesic, antiemetic, anesthetic, antiviral, and other products. The company also offers lipid lowering, antiulcer, anti-parasitic and anti-protozoal, anti-fungal, anti-tuberculosis, and gastroprokinetic agents; and vitamins and minerals, and amino acid supplements.
Renata PLC Fundamentals Summary
| RENATA fundamental statistics | |
|---|---|
| Market cap | ৳89.82b |
| Earnings (TTM) | ৳2.14b |
| Revenue (TTM) | ৳35.69b |
42.1x
P/E Ratio2.5x
P/S RatioIs RENATA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RENATA income statement (TTM) | |
|---|---|
| Revenue | ৳35.69b |
| Cost of Revenue | ৳22.13b |
| Gross Profit | ৳13.56b |
| Other Expenses | ৳11.42b |
| Earnings | ৳2.14b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 29, 2024
| Earnings per share (EPS) | 18.69 |
| Gross Margin | 37.99% |
| Net Profit Margin | 6.01% |
| Debt/Equity Ratio | 47.0% |
How did RENATA perform over the long term?
See historical performance and comparison